Eczema and Migraine: A Pooled Association With Nearly 99% Heterogeneity Needs Caution

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar in an original triathlon scene; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

Recurrent headaches deserve their own assessment even when someone also has eczema. A research association can help draw attention to coexisting problems, but it cannot diagnose migraine or show that treating the skin will prevent headaches.

What the review pooled

The 2024 systematic review and meta-analysis included ten observational studies with a combined reported population of 12,717,747. The authors searched through December 1, 2023. The evidence mixed designs and ways of identifying eczema and headache disorders; it was not a randomized trial of eczema treatment.

Outcome	Pooled odds ratio	95% confidence interval	Heterogeneity
Headache disorder	1.46	1.36–1.56	I²=98%
Migraine	1.32	1.18–1.47	I²=98.9%

A large total sample does not make the studies identical

The I² values show very substantial variation across the study estimates. That statistic does not mean 98.9% of patients had migraine. It also does not measure the probability that eczema caused a headache. Differences in age, diagnosis, eczema severity and study design can all affect the pooled result.

An odds ratio of 1.32 describes a comparison of odds under the combined analyses. It is not a 32% absolute risk, a 32-point probability increase or a forecast that one particular person will develop migraine. A useful individual risk estimate would require appropriate baseline information and a model validated for that purpose.

Direction and mechanism remain uncertain

Some included studies were cross-sectional, recording conditions at a point in time rather than establishing which developed first. Questionnaire-based definitions and diagnosis codes can misclassify cases. The review specifically discusses recall bias, varied disease definitions and substantial heterogeneity as limitations.

Sleep disruption, stress and inflammatory pathways are possible connections to study, not proof of a single causal chain. Even if two diagnoses occur together more often, that does not show that a skin treatment will reduce headache frequency. A cohort association and a treatment trial answer different questions.

Keep a record useful to both care teams

NINDS describes migraine as more than a bad headache and recommends documenting features that can guide assessment. Record episode timing, duration, associated symptoms, medicines taken, previous-night sleep and activities before onset. For a busy adult, a short consistent record is more useful than assuming every episode shares a skin-related trigger.

If itch interrupted sleep, record that alongside the headache rather than labeling it the cause. Include exercise, meals and schedule changes without automatically excluding foods or stopping activity. A clinician can assess recurring or changing symptoms and discuss management suited to the person.

What this means for everyday skin care

Eczema and migraine can each interfere with working, parenting or training. Their coexistence is a reason to communicate symptoms across the care team, not to substitute moisturizer for headache care or to assign all headaches to allergy. #003 has no established role in treating migraine.

The review is useful as a signal for further research and attentive care. It should not become a universal prediction. Our relaxation study explanation separately examines why symptom reports and biological markers also require different interpretations.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.